PPARG

Peroxisome proliferator-activated receptor gamma · P37231 · PPARG on Sugi Atlas →

788,460 patent compounds predicted against PPARG, 433,813 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Rosiglitazone (SCHEMBL5169)	1.00	15/20
Rosiglitazone (SCHEMBL19024)	0.84	15/20
Pioglitazone (SCHEMBL4121)	1.00	14/20
Tesaglitazar (SCHEMBL16594)	1.00	14/20
Pioglitazone (SCHEMBL21843)	1.00	14/20
Pioglitazone (SCHEMBL21844)	1.00	14/20
Exisulind (SCHEMBL25371)	0.80	14/20
Sulindac (SCHEMBL4202)	0.78	14/20
Sulindac (SCHEMBL4203)	0.78	14/20
Rosiglitazone (SCHEMBL19023)	1.00	12/20
SCHEMBL2053	0.50	11/20
SCHEMBL18216	0.45	10/20
SCHEMBL18217	0.45	10/20
Linolenic Acid (SCHEMBL15282)	1.00	8/20
Fenofibric Acid (SCHEMBL16377)	1.00	8/20
Icosapent (SCHEMBL20469)	1.00	8/20
Docosapentaenoic Acid (SCHEMBL20748)	1.00	8/20
SCHEMBL25423	1.00	8/20
SCHEMBL29226	0.96	8/20
SCHEMBL3922	0.59	8/20

Clinical trials — most relevant to PPARG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients	PHASE4	COMPLETED
The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome	PHASE4	COMPLETED
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects	PHASE4	COMPLETED
Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study	PHASE4	WITHDRAWN
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone	PHASE4	COMPLETED
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.	PHASE4	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes	PHASE2	COMPLETED
Bioenergetic Effect of Pioglitazone in CLD-PH	PHASE2	RECRUITING
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery	PHASE2	COMPLETED
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	PHASE2	COMPLETED
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease	PHASE2	COMPLETED
The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis	PHASE2	COMPLETED
Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.	PHASE2	COMPLETED
Pioglitazone Therapy Targeting Fatigue in Breast Cancer	PHASE2	RECRUITING
Rosiglitazone to Reverse Metabolic Defects in Diabetes	PHASE2	COMPLETED
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients	nan	COMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis	nan	COMPLETED
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function	nan	UNKNOWN
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy	nan	COMPLETED
Molecular Pathways Related to Short-term Fasting Response	nan	COMPLETED
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects	nan	UNKNOWN
In and ex Vivo Mitochondrial Function of the Heart	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PPARG binder may also engage these)

Protein	Name	Similarity
O18924	—	1.000	O18924 →
O62807	—	1.000	O62807 →
O18971	—	1.000	O18971 →
P57797	—	1.000	P57797 →
P37238	—	1.000	P37238 →
Q4U3Q4	—	1.000	Q4U3Q4 →
O19052	—	1.000	O19052 →
O88275	—	1.000	O88275 →
Q8HYL6	—	1.000	Q8HYL6 →
Q9XYB7	—	1.000	Q9XYB7 →
P37234	—	1.000	P37234 →
P37230	—	0.999	P37230 →
P23204	—	0.999	P23204 →
O45436	—	0.999	O45436 →
O01930	—	0.999	O01930 →
Q9XTJ4	—	0.998	Q9XTJ4 →
O01931	—	0.998	O01931 →
O35507	—	0.998	O35507 →
PPARA	Peroxisome proliferator-activated receptor alpha	0.998	landscape →
Q0ZAQ8	—	0.998	Q0ZAQ8 →
P37232	—	0.998	P37232 →
O17611	—	0.998	O17611 →
P31396	—	0.998	P31396 →
P79926	—	0.997	P79926 →
Q95N78	—	0.997	Q95N78 →
Q8ITW8	—	0.997	Q8ITW8 →
Q21878	—	0.997	Q21878 →
P49882	—	0.997	P49882 →
Q5RAM2	—	0.997	Q5RAM2 →
P28700	—	0.997	P28700 →